Break it Down: Tryptamine Therapeutics reports positive results for Fibromyalgia patients

Stockhead TV’s Sarah Hughan brings you today’s Break it Down, detailing the new promising trial results from Tryptamine Therapeutics.

Stockhead's Break it Down brings you today's leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Tryptamine Therapeutics' (ASX:TYP) recent trial showing pain reduction in every patient.

The trial was undertaken with the University of Michigan and dosed the patients with Tryptamine’s oral psilocybin formulation.

Tune in to get the latest.

While Tryptamine Therapeutics is a Stockhead advertiser, it did not sponsor this content.

Originally published as Break it Down: Tryptamine Therapeutics reports positive results for Fibromyalgia patients